Arizona PA Loses DEA License Over State Revocation
Published Date: 2/7/2025
Notice
Summary
Herold Pierre-Louis, a physician assistant from Arizona, lost his state license to handle controlled substances, so the DEA has officially revoked his registration to prescribe or dispense these drugs. This means he can no longer legally work with controlled substances starting now, affecting his medical practice and any related income. The decision is final after a legal review, so no more delays or appeals are expected.
Analyzed Economic Effects
3 provisions identified: 0 benefits, 3 costs, 0 mixed.
DEA Registration Revoked for Practitioner
The DEA revoked Certificate of Registration No. MP7845766 issued to Herold Pierre-Louis, P.A., so he can no longer legally prescribe, administer, or dispense controlled substances. This revocation is effective March 10, 2025 and will affect his medical practice and any related income from handling controlled substances.
Pending Renewal and New Registrations Denied
The Order denies any pending applications by Herold Pierre-Louis, P.A., to renew or modify DEA registration No. MP7845766 and denies any other pending application for additional registration in Arizona. The denial is effective March 10, 2025.
State License Revocation Triggers DEA Action
Under 21 U.S.C. 824(a)(3) and 823(g)(1), the DEA may suspend or revoke a practitioner's registration if the practitioner has had their State license suspended or revoked and is no longer authorized under state law to handle controlled substances. The Order cites that possession of state authority to dispense controlled substances is a fundamental condition for maintaining a DEA registration.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11526 — Implementation of the Substance Use-Disorder Prevention That Promotes Opioid Recovery and Treatment for Patients and Communities Act of 2018: Dispensing and Administering Controlled Substances for Medication-Assisted Treatment
Starting July 9, 2026, new rules make it easier for doctors and pharmacies to provide medicine that helps people recover from opioid addiction. These changes affect healthcare providers by expanding who can give medication-assisted treatment and how pharmacies can deliver these medicines. The goal? Faster, safer access to treatment with clear rules that save time and support recovery.
2026-10128 — Revision of Applications for Manufacturing and Procurement Quotas
The DEA wants to update how companies apply for permission to make and buy certain controlled drugs and chemicals. These changes will make the rules clearer, help prevent drug shortages, and ensure enough supply for medical and scientific needs. If you’re a manufacturer or involved in this process, get ready to follow new steps and share your thoughts by July 20, 2026.
2026-12140 — Importer of Controlled Substances Application: Scottsdale Research Institute
Scottsdale Research Institute wants to become an official importer of some controlled substances like ibogaine and marijuana. People who make or import these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could affect how these substances are brought into the U.S., but no costs or fees are mentioned yet.
2026-12144 — Importer of Controlled Substances Application: Wedgewood Pharmacy LLC
Wedgewood Pharmacy LLC wants to become an official importer of certain strong controlled substances, like Etorphine HCL and Thiafentanil. This affects drug manufacturers and others in the supply chain who can comment or request a hearing by July 17, 2026. No direct costs are mentioned, but the decision could impact how these drugs enter the U.S. market.
2026-12143 — Importer of Controlled Substances Application: AndersonBrecon, Inc. DBA PCI Pharma Services
AndersonBrecon, Inc. DBA PCI Pharma Services wants to become an official importer of certain controlled substances, including some strong drugs like tetrahydrocannabinols. People and companies involved with these drugs can share their thoughts or ask for a hearing by July 17, 2026. This move could impact how these substances are brought into the U.S., but no costs or fees were mentioned yet.
2026-11909 — Importer of Controlled Substances Application: Cerilliant Corporation
Cerilliant Corporation wants to become an official importer of certain controlled substances, including some drugs that need strict government oversight. People and companies involved with these substances can share their thoughts or ask for a hearing by July 15, 2026. This move could affect how these drugs enter the U.S. and might impact businesses handling them.
Previous / Next Documents
Previous: 2025-02337 — Certain Video Capable Electronic Devices, Including Computers, Streaming Devices, Televisions, Cameras, and Components and Modules Thereof; Notice of Request for Submissions on the Public Interest
The government is checking if certain video devices like computers, TVs, and cameras broke some rules. They want your thoughts on what should happen if a violation is found, especially about fixes and money matters. If you’re part of the public or a government agency, you can share your opinions before decisions are made in early 2025.
Next: 2025-02341 — James T. Craig, D.D.S.; Decision and Order
James T. Craig, a dentist from Colorado, lost his DEA registration because he no longer has the legal right to handle controlled substances in his state. He didn’t ask for a hearing to challenge this, so the DEA officially revoked his registration, which expired in August 2024. This means he can’t prescribe or manage controlled drugs anymore, and the decision is final.